Cui G et al. (2019), VX-770-mediated potentiation of numerous human ...

XB-ART-57641

Sci Rep 2019 Sep 17;91:13460. doi: 10.1038/s41598-019-49921-4.

Show Gene links Show Anatomy links

VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level.

Cui G , Stauffer BB , Imhoff BR , Rab A , Hong JS , Sorscher EJ , McCarty NA .

???displayArticle.abstract???
VX-770 (ivacaftor) is approved for clinical use in CF patients bearing multiple CFTR mutations. VX-770 potentiated wildtype CFTR and several disease mutants expressed in oocytes in a manner modulated by PKA-mediated phosphorylation. Potentiation of some other mutants, including G551D-CFTR, was less dependent upon the level of phosphorylation, likely related to the severe gating defects in these mutants exhibited in part by a shift in PKA sensitivity to activation, possibly due to an electrostatic interaction of D551 with K1250. Phosphorylation-dependent potentiation of wildtype CFTR and other variants also was observed in epithelial cells. Hence, the efficacy of potentiators may be obscured by a ceiling effect when drug screening is performed under strongly phosphorylating conditions. These results should be considered in campaigns for CFTR potentiator discovery, and may enable the expansion of VX-770 to CF patients bearing ultra-orphan CFTR mutations.

???displayArticle.pubmedLink??? 31530897
???displayArticle.link??? Sci Rep
???displayArticle.grants??? [+]

Genes referenced: cftr dtl

???displayArticle.disOnts??? cystic fibrosis

???attribute.lit??? ???displayArticles.show???

	Figure 1. Single channel behavior in WT-CFTR is different in high and low PKA concentration. Representative single-channel current traces are shown for WT-CFTR in low PKA (A, 6.4 U/ml) and high PKA (B, 127.6 U/ml), from one inside-out membrane patch excised from Xenopus oocytes, with symmetrical 150 mM Cl− solution in the presence of 1 mM MgATP. All traces were recorded at Vm = -100 mV. c = closed state; f = full open state. All-points amplitude histograms are shown in the right panels, where solid lines are fit results to a Gaussian function. Single channel amplitude (C), open probability (n = 4) (D), and mean burst duration (E) of WT-CFTR in low and high PKA conditions are shown. n = 5. (F) Representative macropatch currents of WT-CFTR recorded in inside-out mode with symmetrical 150 mM Cl− solution under the following experimental conditions: channels were fully activated in 1 mM MgATP + 6.4 U/ml PKA followed by 1 mM MgATP + 127.6 U/ml PKA. A voltage-ramp protocol described in the Methods section was applied every 5 s. ▼, 10 µM CFTRinh172.
	Figure 2. Cytoplasmic VX-770 potentiated WT-, E193K-, K1060T-, and N1303K-CFTR in a manner sensitive to phosphorylation-level. (A) Three amino acids E193, K1060, N1303 are shown as red spheres in the closed state human CFTR Cryo-EM model adopted from previous publication and prepared with PyMOL5. TM6 is indicated in blue shades. Representative macropatch currents of CFTR (WT: (B,C); E193K: (D,E); K1060T: (F,G); N1303K: (H,I)) were recorded in inside-out mode with symmetrical 150 mM Cl− solution under the following experimental conditions: channels were activated in 1 mM MgATP + 6.4 U/ml (low PKA) or 127.6 U/ml PKA (high PKA) for ten minutes followed with addition of 0.2 µM VX-770 in the continuing presence of MgATP + PKA for about three minutes; currents then were blocked by 10 µM CFTRinh172 (▼). A voltage-ramp protocol described in the Methods section was applied every 5 s. J. Summary data for fractional increase of WT- and three disease CFTR mutants by VX-770 under each set of conditions are shown (Fractional increase = I(ATP+PKA+VX-770)/I(ATP+PKA) − 1). Black bars are from experiments with high PKA and gray bars are from experiments with low PKA. WT: n = 6 for high PKA; n = 5 for low PKA. E193K, n = 5 for both high and low PKA. N1303K: n = 5 for high PKA; n = 4 for low PKA. K1060T, n = 5 for high PKA; n = 8 for low PKA. P < 0.05, P < 0.01 and **P < 0.001 compared to high PKA condition.
	Figure 3. VX-770 potentiated F508del-, P67L-, and G551D-CFTR in a manner less sensitive to phosphorylation level. (A) Three amino acids F508, P67, and G551 are shown as red spheres in the closed state human CFTR Cryo-EM model adopted from previous publication and prepared with PyMOL5. TM6 is indicated in blue shades. Representative macropatch currents of CFTR (F508del: (B,C); P67L: (D,E); G551D: (F,G)) recorded in inside-out mode with the same experimental conditions as Fig. 2. ▼, 10 µM CFTRinh172. (H) Summary data for fractional increase of WT- and three disease mutant CFTR variants by VX-770 under high and low PKA are shown. F508del: n = 10 for high PKA; n = 5 for low PKA. P67L: n = 6 for high PKA; n = 5 for low PKA. G551D: n = 5 for high PKA; n = 6 for low PKA. P < 0.05 and **P < 0.001 compared to high PKA condition.
	Figure 4. VX-770 potentiated F508S- and F508C-CFTR similarly to F508del-CFTR. VX-770 (0.2 µM) potentiated F508S-CFTR in high (A) and low (B) PKA concentrations with 1 mM MgATP. Representative current traces of F508C-CFTR potentiated by VX-770 in high (C) and low PKA (D) conditions also are shown. ▼, 10 µM CFTRinh172. Summary data for F508S- and F508C-CFTR potentiated by VX-770 are shown in (H). F508C: n = 7 for high PKA; n = 6 for low PKA. F508S: n = 6 for high PKA; n = 4 for low PKA. Representative current traces of F508del- (E), F508S- (F), and F508C- (G) CFTR activated by low PKA then by high PKA in the presence of 1 mM MgATP are shown. Summary data for the ratio of three F508 mutants in high and low PKA conditions are shown in panel I and calculated based on the equation in Fig. 1. n = 6 for F508del; n = 6 for F508S; n = 4 for F508C. *P < 0.05 compared to WT.
	Figure 5. Activation rates of P67L- and N66S-CFTR are lower compared to WT-CFTR under high PKA conditions. Both P67 and N66 are located in the Lasso motif shown in panel I as red spheres in the closed state human CFTR Cryo-EM model prepared with PyMOL5. TM6 is indicated in blue color. (A,B) P67L- and N66S- activation durations are significantly longer than WT-CFTR in 1 mM MgATP + 127.6 U/ml PKA condition. (C,D) Both P67L- and N66S-CFTR exhibited a shift in PKA sensitivity. (E,F) Representative current traces of P67L potentiated by VX-770 after channels were fully activated in both high and low PKA conditions. (G,H) Representative current traces of N66S potentiated by VX-770 after channels were fully activated in both high and low PKA condition. ▼, 10 µM CFTRinh172. Summary data for activation durations are shown in panel (J). n = 30 for WT, n = 9 for P67L, and n = 10 for N66S. **P < 0.001 compared to WT. Summary data for the ratio of P67L- and N66S-CFTR currents in low and high concentration of PKA are shown in panel (K) calculated based on the equation in Fig. 1. P < 0.05 compared to WT. Summary data of P67L- and N66S-CFTR potentiated by VX-770 are shown in panel (L). n = 6 for both P67L and N66S in both low and high PKA conditions.
	Figure 6. Activation of G551D-CFTR is slowed compared to WT-CFTR under the same experimental conditions. Representative current traces of WT- (A) and G551D-CFTR (B) recorded in symmetrical 150 mM Cl− solution with 1 mM MgATP + 127.6 U/ml PKA using excised inside-out macropatch. The recordings were arbitrarily halted at 52 minutes even if the channels were not fully activated. (C) G551A-, (D) K1250A-, and (E) G551D/K1250A-CFTR activation durations were determined under the same experimental conditions as (A,B). Control, intracellular solution alone, without ATP or PKA. ▼, 10 µM CFTRinh172. Summary data are shown in panel (F). The estimated activation duration of G551D-CFTR is significantly longer than that of WT-CFTR (***P < 0.001 compared to WT). The activation duration of K1250A-CFTR is similar to that of WT-CFTR. Activation durations of G551A-, K1250A-, and G551D/K1250A-CFTR were significantly shorter compared to G551D-CFTR (#P < 0.001 compared to G551D-CFTR) (F). n = 30 each for WT-, G551D-, and G551A-CFTR. n = 13 for K1250A-CFTR. n = 18 for G551D/K1250A-CFTR. (G). Amino acid G551 is shown as red spheres and K1250 is shown as blue spheres in the closed state (0 ns) and open state (10 ns) simulations of the CFTR homology model adopted from our previous publication39 and prepared with PyMOL5. TM1–6 are indicated in blue shades and TM7–12 are indicated in orange shades. NBD1 is indicated in light blue and NBD2 is indicated in light green.
	Figure 7. Cytoplasmic VX-770 potentiates G551D- and G551A-CFTR in a phosphorylation-dependent manner when channels were fully activated, albeit with much lower efficacy. Representative current traces of G551D- (A,B) and G551A-CFTR (C,D) recorded under the same conditions as in Fig. 3, except that channels were fully activated in 1 mM MgATP plus low or high PKA before addition of VX-770 in the continuing presence of ATP and PKA. ▼, 10 µM CFTRinh172. Summary data for effects of 0.2 µM VX-770 on WT-, G551D-, and G551A-CFTR are shown in (E). P < 0.05, P < 0.01, and **P < 0.001 compared to high PKA. G551D: n = 8 for high PKA; n = 7 for low PKA. G551A: n = 5 for high PKA; n = 6 for low PKA. Data for WT-CFTR are the same as in Fig. 2.

References [+] :

Avramescu, Mutation-specific downregulation of CFTR2 variants by gating potentiators. 2017, Pubmed

Avramescu, Mutation-specific downregulation of CFTR2 variants by gating potentiators. 2017, Pubmed
Baker, CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. 2007, Pubmed
Bompadre, G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. 2007, Pubmed
Bozoky, Regulatory R region of the CFTR chloride channel is a dynamic integrator of phospho-dependent intra- and intermolecular interactions. 2013, Pubmed
Bozoky, Structural changes of CFTR R region upon phosphorylation: a plastic platform for intramolecular and intermolecular interactions. 2013, Pubmed
Cai, Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. 2006, Pubmed
Caputo, Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. 2009, Pubmed
Carson, The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. 1995, Pubmed
Casals, Extensive analysis of 40 infertile patients with congenital absence of the vas deferens: in 50% of cases only one CFTR allele could be detected. 1995, Pubmed
Chappe, Phosphorylation of CFTR by PKA promotes binding of the regulatory domain. 2005, Pubmed
Chen, Altering intracellular pH reveals the kinetic basis of intraburst gating in the CFTR Cl- channel. 2017, Pubmed
Cholon, Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. 2014, Pubmed
Chong, Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization. 2015, Pubmed
Csanády, Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA. 2005, Pubmed , Xenbase
Csanády, Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains. 2000, Pubmed , Xenbase
Cui, Three charged amino acids in extracellular loop 1 are involved in maintaining the outer pore architecture of CFTR. 2014, Pubmed , Xenbase
Cui, Potentiators exert distinct effects on human, murine, and Xenopus CFTR. 2016, Pubmed , Xenbase
Cui, Murine and human CFTR exhibit different sensitivities to CFTR potentiators. 2015, Pubmed , Xenbase
Cui, The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. 2006, Pubmed
Cui, Two salt bridges differentially contribute to the maintenance of cystic fibrosis transmembrane conductance regulator (CFTR) channel function. 2013, Pubmed , Xenbase
Dalemans, Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. , Pubmed
DeStefano, Physiological and pharmacological characterization of the N1303K mutant CFTR. 2018, Pubmed
Dong, Human-mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR-ΔF508 processing and alter its gating defect. 2012, Pubmed
Drumm, Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. 1991, Pubmed , Xenbase
Dulhanty, Mutation of potential phosphorylation sites in the recombinant R domain of the cystic fibrosis transmembrane conductance regulator has significant effects on domain conformation. 1995, Pubmed
Eckford, Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. 2012, Pubmed
Gadsby, The ABC protein turned chloride channel whose failure causes cystic fibrosis. 2006, Pubmed
Gentzsch, Ion Channel Modulators in Cystic Fibrosis. 2018, Pubmed
Gunderson, Conformational states of CFTR associated with channel gating: the role ATP binding and hydrolysis. 1995, Pubmed
Harris, Cholera. 2012, Pubmed
Howell, ATP hydrolysis by a CFTR domain: pharmacology and effects of G551D mutation. 2000, Pubmed
Hwang, Gating of the CFTR Cl- channel by ATP-driven nucleotide-binding domain dimerisation. 2009, Pubmed
Jih, Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. 2013, Pubmed
Langron, Potentiation of the cystic fibrosis transmembrane conductance regulator by VX-770 involves stabilization of the pre-hydrolytic, O1 state. 2018, Pubmed
Liu, Molecular Structure of the Human CFTR Ion Channel. 2017, Pubmed , Xenbase
Liu, Structural identification of a hotspot on CFTR for potentiation. 2019, Pubmed
Lukacs, The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. 1993, Pubmed
Matthes, Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). 2016, Pubmed
Pedemonte, Influence of cell background on pharmacological rescue of mutant CFTR. 2010, Pubmed
Rahman, Modeling the conformational changes underlying channel opening in CFTR. 2013, Pubmed
Rowe, Nasal potential difference measurements to assess CFTR ion channel activity. 2011, Pubmed
Rowe, Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. 2017, Pubmed
Sabusap, Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases. 2016, Pubmed
Seavilleklein, PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR. 2008, Pubmed
Seibert, Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel. 1997, Pubmed
Stauffer, Bacterial Sphingomyelinase is a State-Dependent Inhibitor of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR). 2017, Pubmed , Xenbase
Van Goor, Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. 2014, Pubmed
Van Goor, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. 2009, Pubmed
Veit, From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. 2016, Pubmed
Veit, Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. 2014, Pubmed
Vergani, On the mechanism of MgATP-dependent gating of CFTR Cl- channels. 2003, Pubmed , Xenbase
Wang, ATP-independent CFTR channel gating and allosteric modulation by phosphorylation. 2010, Pubmed
Wang, Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs. 2005, Pubmed
Wang, An electrostatic interaction at the tetrahelix bundle promotes phosphorylation-dependent cystic fibrosis transmembrane conductance regulator (CFTR) channel opening. 2014, Pubmed
Wilkinson, CFTR: the nucleotide binding folds regulate the accessibility and stability of the activated state. 1996, Pubmed , Xenbase
Xu, Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR. 2014, Pubmed
Yeh, Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770. 2019, Pubmed
Yeh, A common mechanism for CFTR potentiators. 2017, Pubmed
Yousef, Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation. 2015, Pubmed
Yu, Ivacaftor potentiation of multiple CFTR channels with gating mutations. 2012, Pubmed
Zhang, Conformational Changes of CFTR upon Phosphorylation and ATP Binding. 2017, Pubmed
Zhang, Determination of the functional unit of the cystic fibrosis transmembrane conductance regulator chloride channel. One polypeptide forms one pore. 2005, Pubmed
Zhang, Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator. 2016, Pubmed
Zhou, Voltage-dependent flickery block of an open cystic fibrosis transmembrane conductance regulator (CFTR) channel pore. 2001, Pubmed

	Figure 1. Single channel behavior in WT-CFTR is different in high and low PKA concentration. Representative single-channel current traces are shown for WT-CFTR in low PKA (A, 6.4 U/ml) and high PKA (B, 127.6 U/ml), from one inside-out membrane patch excised from Xenopus oocytes, with symmetrical 150 mM Cl− solution in the presence of 1 mM MgATP. All traces were recorded at Vm = -100 mV. c = closed state; f = full open state. All-points amplitude histograms are shown in the right panels, where solid lines are fit results to a Gaussian function. Single channel amplitude (C), open probability (n = 4) (D), and mean burst duration (E) of WT-CFTR in low and high PKA conditions are shown. n = 5. (F) Representative macropatch currents of WT-CFTR recorded in inside-out mode with symmetrical 150 mM Cl− solution under the following experimental conditions: channels were fully activated in 1 mM MgATP + 6.4 U/ml PKA followed by 1 mM MgATP + 127.6 U/ml PKA. A voltage-ramp protocol described in the Methods section was applied every 5 s. ▼, 10 µM CFTRinh172.
	Figure 2. Cytoplasmic VX-770 potentiated WT-, E193K-, K1060T-, and N1303K-CFTR in a manner sensitive to phosphorylation-level. (A) Three amino acids E193, K1060, N1303 are shown as red spheres in the closed state human CFTR Cryo-EM model adopted from previous publication and prepared with PyMOL5. TM6 is indicated in blue shades. Representative macropatch currents of CFTR (WT: (B,C); E193K: (D,E); K1060T: (F,G); N1303K: (H,I)) were recorded in inside-out mode with symmetrical 150 mM Cl− solution under the following experimental conditions: channels were activated in 1 mM MgATP + 6.4 U/ml (low PKA) or 127.6 U/ml PKA (high PKA) for ten minutes followed with addition of 0.2 µM VX-770 in the continuing presence of MgATP + PKA for about three minutes; currents then were blocked by 10 µM CFTRinh172 (▼). A voltage-ramp protocol described in the Methods section was applied every 5 s. J. Summary data for fractional increase of WT- and three disease CFTR mutants by VX-770 under each set of conditions are shown (Fractional increase = I(ATP+PKA+VX-770)/I(ATP+PKA) − 1). Black bars are from experiments with high PKA and gray bars are from experiments with low PKA. WT: n = 6 for high PKA; n = 5 for low PKA. E193K, n = 5 for both high and low PKA. N1303K: n = 5 for high PKA; n = 4 for low PKA. K1060T, n = 5 for high PKA; n = 8 for low PKA. P < 0.05, P < 0.01 and **P < 0.001 compared to high PKA condition.
	Figure 3. VX-770 potentiated F508del-, P67L-, and G551D-CFTR in a manner less sensitive to phosphorylation level. (A) Three amino acids F508, P67, and G551 are shown as red spheres in the closed state human CFTR Cryo-EM model adopted from previous publication and prepared with PyMOL5. TM6 is indicated in blue shades. Representative macropatch currents of CFTR (F508del: (B,C); P67L: (D,E); G551D: (F,G)) recorded in inside-out mode with the same experimental conditions as Fig. 2. ▼, 10 µM CFTRinh172. (H) Summary data for fractional increase of WT- and three disease mutant CFTR variants by VX-770 under high and low PKA are shown. F508del: n = 10 for high PKA; n = 5 for low PKA. P67L: n = 6 for high PKA; n = 5 for low PKA. G551D: n = 5 for high PKA; n = 6 for low PKA. P < 0.05 and **P < 0.001 compared to high PKA condition.
	Figure 4. VX-770 potentiated F508S- and F508C-CFTR similarly to F508del-CFTR. VX-770 (0.2 µM) potentiated F508S-CFTR in high (A) and low (B) PKA concentrations with 1 mM MgATP. Representative current traces of F508C-CFTR potentiated by VX-770 in high (C) and low PKA (D) conditions also are shown. ▼, 10 µM CFTRinh172. Summary data for F508S- and F508C-CFTR potentiated by VX-770 are shown in (H). F508C: n = 7 for high PKA; n = 6 for low PKA. F508S: n = 6 for high PKA; n = 4 for low PKA. Representative current traces of F508del- (E), F508S- (F), and F508C- (G) CFTR activated by low PKA then by high PKA in the presence of 1 mM MgATP are shown. Summary data for the ratio of three F508 mutants in high and low PKA conditions are shown in panel I and calculated based on the equation in Fig. 1. n = 6 for F508del; n = 6 for F508S; n = 4 for F508C. *P < 0.05 compared to WT.
	Figure 5. Activation rates of P67L- and N66S-CFTR are lower compared to WT-CFTR under high PKA conditions. Both P67 and N66 are located in the Lasso motif shown in panel I as red spheres in the closed state human CFTR Cryo-EM model prepared with PyMOL5. TM6 is indicated in blue color. (A,B) P67L- and N66S- activation durations are significantly longer than WT-CFTR in 1 mM MgATP + 127.6 U/ml PKA condition. (C,D) Both P67L- and N66S-CFTR exhibited a shift in PKA sensitivity. (E,F) Representative current traces of P67L potentiated by VX-770 after channels were fully activated in both high and low PKA conditions. (G,H) Representative current traces of N66S potentiated by VX-770 after channels were fully activated in both high and low PKA condition. ▼, 10 µM CFTRinh172. Summary data for activation durations are shown in panel (J). n = 30 for WT, n = 9 for P67L, and n = 10 for N66S. **P < 0.001 compared to WT. Summary data for the ratio of P67L- and N66S-CFTR currents in low and high concentration of PKA are shown in panel (K) calculated based on the equation in Fig. 1. P < 0.05 compared to WT. Summary data of P67L- and N66S-CFTR potentiated by VX-770 are shown in panel (L). n = 6 for both P67L and N66S in both low and high PKA conditions.
	Figure 6. Activation of G551D-CFTR is slowed compared to WT-CFTR under the same experimental conditions. Representative current traces of WT- (A) and G551D-CFTR (B) recorded in symmetrical 150 mM Cl− solution with 1 mM MgATP + 127.6 U/ml PKA using excised inside-out macropatch. The recordings were arbitrarily halted at 52 minutes even if the channels were not fully activated. (C) G551A-, (D) K1250A-, and (E) G551D/K1250A-CFTR activation durations were determined under the same experimental conditions as (A,B). Control, intracellular solution alone, without ATP or PKA. ▼, 10 µM CFTRinh172. Summary data are shown in panel (F). The estimated activation duration of G551D-CFTR is significantly longer than that of WT-CFTR (***P < 0.001 compared to WT). The activation duration of K1250A-CFTR is similar to that of WT-CFTR. Activation durations of G551A-, K1250A-, and G551D/K1250A-CFTR were significantly shorter compared to G551D-CFTR (#P < 0.001 compared to G551D-CFTR) (F). n = 30 each for WT-, G551D-, and G551A-CFTR. n = 13 for K1250A-CFTR. n = 18 for G551D/K1250A-CFTR. (G). Amino acid G551 is shown as red spheres and K1250 is shown as blue spheres in the closed state (0 ns) and open state (10 ns) simulations of the CFTR homology model adopted from our previous publication39 and prepared with PyMOL5. TM1–6 are indicated in blue shades and TM7–12 are indicated in orange shades. NBD1 is indicated in light blue and NBD2 is indicated in light green.
	Figure 7. Cytoplasmic VX-770 potentiates G551D- and G551A-CFTR in a phosphorylation-dependent manner when channels were fully activated, albeit with much lower efficacy. Representative current traces of G551D- (A,B) and G551A-CFTR (C,D) recorded under the same conditions as in Fig. 3, except that channels were fully activated in 1 mM MgATP plus low or high PKA before addition of VX-770 in the continuing presence of ATP and PKA. ▼, 10 µM CFTRinh172. Summary data for effects of 0.2 µM VX-770 on WT-, G551D-, and G551A-CFTR are shown in (E). P < 0.05, P < 0.01, and **P < 0.001 compared to high PKA. G551D: n = 8 for high PKA; n = 7 for low PKA. G551A: n = 5 for high PKA; n = 6 for low PKA. Data for WT-CFTR are the same as in Fig. 2.